vaccine

Last week the vaccine developer Novavax’s stock dropped precipitously when their RSV F-protein recombinant nanoparticle vaccine did not demonstrate vaccine efficacy in the Phase III Resolve trial.  You can read more about the failure at FierceBiotch.  The drug was aimed at treating adults with respiratory syncytial virus (RSV). RSV is generally a mild cold-like illness in healthy individuals, but can be much more serious in small children and older adults.

Here’s a thought: What if we were to put just a fraction of the resources pouring into biotech solutions into implementing what is already known to optimize immune function? For example, what if every parent of young children understood the importance of optimizing the health of the microbiome through real high quality nutrition and the profound effect that this has on true immunity?

What if every elderly person in a nursing home was seen by a physician that recognized the significance of optimizing vitamin D levels and the powerful effects that this pennies-a-day solution has on immune system function and our general susceptibility to any pathogen?

Don’t worry…biotech will not give up on seeking to solve every one of your health problems for you.  The Bill & Melinda Gates Foundation has given $89 million to research a maternal immunization program for RSV, using the exact same Novavax vaccine described above.  But its time for all of us to take a much less passive approach to our “healthcare” and realize the incredible tools we already have within reach for immune system optimization and disease prevention.

1 Comment on Another vaccine failure: Novavax’s stock drops 80% ($1.5 billion) as its RSV vaccine fails to offer immunity

Leave a Reply

Your email address will not be published. Required fields are marked *